NASDAQ · PRFX
Healthcare · Drug Manufacturers - Specialty & Generic
$1.00
Down-$0.00 (-0.29%)
Updated Aug 21, 2026, 10:22 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
PRFX closed at $1.00 after 21 trading sessions, down 13.04% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 20, 2026 | $0.9844 | $1.01 | $0.9707 | $1.00 | 53.22K |
| Aug 19, 2026 | $0.9353 | $1.03 | $0.912 | $1.01 | 126.65K |
| Aug 18, 2026 | $0.96 | $0.97 | $0.94 | $0.9417 | 98.75K |
| Aug 17, 2026 | $1.00 | $1.02 | $0.9405 | $0.9702 | 156.76K |
| Aug 14, 2026 | $1.07 | $1.08 | $0.9523 | $1.03 | 353.8K |
| Aug 13, 2026 | $1.03 | $1.20 | $1.01 | $1.20 | 5.55M |
| Aug 12, 2026 | $1.05 | $1.075 | $1.02 | $1.03 | 79.67K |
| Aug 11, 2026 | $1.0624 | $1.11 | $1.03 | $1.10 | 97.37K |
| Aug 10, 2026 | $1.08 | $1.17 | $1.04 | $1.05 | 137.34K |
| Aug 7, 2026 | $1.085 | $1.12 | $1.03 | $1.04 | 250.5K |
| Aug 6, 2026 | $1.07 | $1.13 | $1.0605 | $1.10 | 65.51K |
| Aug 5, 2026 | $1.15 | $1.18 | $1.10 | $1.10 | 45.96K |
| Aug 4, 2026 | $1.00 | $1.15 | $0.998 | $1.13 | 195.6K |
| Aug 3, 2026 | $1.01 | $1.04 | $0.99 | $1.00 | 89.61K |
| Jul 31, 2026 | $1.02 | $1.03 | $0.99 | $1.00 | 120.65K |
| Jul 30, 2026 | $0.97 | $1.1087 | $0.97 | $1.03 | 220.6K |
| Jul 29, 2026 | $1.06 | $1.2882 | $0.9786 | $0.991 | 624.84K |
| Jul 28, 2026 | $1.07 | $1.115 | $1.04 | $1.07 | 104.76K |
| Jul 27, 2026 | $1.13 | $1.20 | $1.08 | $1.09 | 339.71K |
| Jul 24, 2026 | $1.15 | $1.19 | $1.102 | $1.135 | 97.03K |
| Jul 23, 2026 | $1.20 | $1.20 | $1.13 | $1.15 | 85.42K |
The latest Smart Investors Daily articles mentioning PRFX.
PRFX research
Company profile and research snapshot.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 24, 2024 | Maxim Group | Hold | — |
| Jun 26, 2024 | Maxim Group | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 27, 2026
First-Half 2026 and Recent Highlights:Raised $10 million through the Company's equity line facility, substantially strengthening the balance sheetLayerBio advancing the operational and clinical preparations required
Benzinga · Mar 27, 2026
LayerBio's OcuRing™-K program and broader ocular platform strengthen PRF's healthcare growth strategyDeepSolar advances from acquisition to early commercial deployment
Benzinga · Mar 17, 2026
PRF Technologies Ltd. (NASDAQ:PRFX) ("PRF" or the "Company") today announced a commercial collaboration agreement with Blade Ranger Ltd. (TASE: BLRN) designed to accelerate the commercial expansion of its DeepSolar
Benzinga · Feb 11, 2026
PRF Technologies (Nasdaq: PRFX) ("PRF" or the "Company"), through its DeepSolar™ AI-driven solar analytics business unit, today announced the signing of a software-as-a-service (SaaS) agreement with Shikun &
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PRFX.
No results
No recent SID articles mention PRFX.
